drugset / Trial / NCT05553886
S086 Tablets for Chronic Heart Failure With Reduced Ejection Fraction
RandomizedParallel-groupQuadruple-blindTreatment
Summary
A randomized, double-blind, positive-drug parallel controlled, multicenter phase III trial of the efficacy and safety of S086 tablets in patients with chronic heart failure with reduced ejection fraction (HFrEF)
Timeline
- Start
- 2021-12-21
- Primary completion
- 2025-12-31
- Completion
- 2026-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Sacubitril alisartan calcium | Unknown | 60 mg | — |
| Subject | Sacubitril alisartan calcium | Unknown | 120 mg | — |
| Subject | Sacubitril alisartan calcium | Unknown | 180 mg | — |
| Subject | Sacubitril alisartan calcium | Unknown | 240 mg | — |
| Subject | Sacubitril-Valsartan | Unknown | 50 mg | — |
| Subject | Sacubitril-Valsartan | Unknown | 100 mg | — |